Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

Launched by SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS · Mar 1, 2019

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to treat prostate cancer using a technique called image-guided focal brachytherapy. The researchers believe that by using a specific type of imaging called 18F-DCFPyl PET/CT, they can better identify which tumors are significant and need treatment, while avoiding areas of the prostate that are not affected or have less serious disease. This approach aims to target only the tumors that need treatment, which could help reduce side effects for patients.

To participate in this trial, men aged 65 to 74 who have been diagnosed with a specific type of prostate cancer (Gleason scores of 6-7) and meet certain health criteria may qualify. Participants will undergo imaging tests as part of their treatment planning and will receive the brachytherapy focused on the identified tumors. It’s important to note that individuals with a history of pelvic radiation treatment or certain medical conditions may not be eligible. This trial is currently recruiting participants, and those interested will need to provide consent before joining.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Adenocarcinoma of the prostate
• • Performance Status \< 2
• • Clinical stages (not radiographic stage) T1c - T2a, Nx or N0, Mx or M0
• • Gleason 6-7 cancer
• • Prostate volume \< 60 cc (if MRI and TRUS have conflicting values, then MRI value will be utilized)
• • International Prostate symptom score (IPSS) 20 or less
• • Ability to undergo DCF-Pyl PSMA PET as part of pretreatment staging
• • Signed study-specific consent form prior to registration
• Exclusion Criteria:
• • Prior history of pelvic radiation therapy
• • Major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of treatment and would interfere with follow up.
• • Implanted device or apparatus which obstruct visibility of the implanted sources on fluoroscopy
• • Metallic implants, claustrophobia not amenable to medication, or known contraindications to undergoing MR scanning
• • History of other malignancy diagnosed within the past 3 years